Approval · Notice of Compliance 14023 · 2013
ZITHROMAX: Notice of Compliance 14023
Issued January 15, 2013
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 14023
- Date
- January 15, 2013
- Company
- Pfizer Canada UlcKirkland, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Alternate drug product manufacturing, packaging and testing site
- Therapeutic class
- Antibiotic
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ZITHROMAX | Not yet assigned | — |
| ZITHROMAX FOR INTRAVENOUS INJECTION | Not yet assigned | — |
Medicinal ingredients
- AZITHROMYCIN DIHYDRATE 100 MG per 5ML
- AZITHROMYCIN DIHYDRATE 200 MG per 5ML
- AZITHROMYCIN DIHYDRATE 250 MG per TAB
- AZITHROMYCIN DIHYDRATE 500 MG per TAB
- AZITHROMYCIN DIHYDRATE 600 MG per TAB
- AZITHROMYCIN DIHYDRATE 500 MG per 10ML
- AZITHROMYCIN 500 MG per VIAL